Diagnostic importance of admission platelet volume indices in patients with acute chest pain suggesting acute coronary syndrome  by Dehghani, Mohammad Reza et al.
ww.sciencedirect.com
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 6 2 2e6 2 8Available online at wScienceDirect
journal homepage: www.elsevier .com/locate / ih jOriginal ArticleDiagnostic importance of admission platelet
volume indices in patients with acute chest pain
suggesting acute coronary syndromeMohammad Reza Dehghani a, Leila Taghipour-Sani a, Yousef Rezaei b,*,
Rahim Rostami c
a Department of Cardiology, Seyyed-al-Shohada Heart Center, Urmia University of Medical Sciences, Urmia, Iran
b Seyyed-al-Shohada Heart Center, Urmia University of Medical Sciences, Urmia, Iran
c Department of Clinical Biochemistry & Nutrition, Urmia University of Medical Sciences, Urmia, Irana r t i c l e i n f o
Article history:
Received 1 November 2013
Accepted 17 October 2014
Available online 10 November 2014
Keywords:
Acute coronary syndrome
Platelet volume indices
Mean platelet volume
Platelet distribution width
Platelet large cell ratio* Corresponding author. Tel.: þ98 912 623 18
E-mail addresses: mr.dehghani@gmail.co
com, dr.yousefrezaei@gmail.com (Y. Rezaei)
http://dx.doi.org/10.1016/j.ihj.2014.10.415
0019-4832/Copyright © 2014, Cardiological Soa b s t r a c t
Objective: Acute coronary syndrome (ACS) is a challenging issue in cardiovascular medicine.
Given platelet role in atherothrombosis, we sought to determinewhether platelet indices can
be used as diagnostic tests for patients who suffered from an acute chest discomfort.
Methods: We prospectively enrolled 862 patients with an acute chest pain and 184 healthy
matched controls. They were divided into four groups: 184 controls, 249 of non-ACS, 421 of
unstable angina (UA), and 192 of myocardial infarction (MI) cases. Blood samples were
collected at admission to the emergency department for routine hematologic tests.
Results: Themean platelet volume (MPV), platelet distributionwidth (PDW), and platelet large
cell ratio (P-LCR) were significantly greater in patients with MI compared with those of non-
ACS or control subjects. Negative and significant correlations existed between MPV, PDW,
and P-LCR values and platelet count (P < 0.001). Receiver operating characteristic (ROC) curves
showed that the MPV, PDW, and P-LCR with cut-off values of 9.15 fL, 11.35 fL, and 20.25% and
with area under the curves of 0.563, 0.557, and 0.560, respectively, detectedMI patients among
those who had chest discomfort. The sensitivities and specificities were found to be 72% and
40%, 73% and 37%, and 68% and 44% for MPV, PDW, and P-LCR, respectively.
Conclusion: An elevated admission MPV, PDW, and P-LCR may be of benefit to detect chest
pain resulting in MI from that of non-cardiac one, and also for risk stratification of patients
who suffered from an acute chest discomfort.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Introduction
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myocardial ischemia.2 Troponin and the MB isoenzyme of
creatine kinase (CK-MB) are the routine biochemical markers,
which are used to detect ACS. Troponin, as the most sensitive
and tissue-specific cardiac marker, is now considered as the
gold-standard biochemical tool for ACS risk stratification;
however, it is undetectable in about 40e60% of patients
suffering from an ACS.3 Therefore, using a multimarker
approach may be of benefit to diagnose the spectrum of clin-
ical manifestation, like ACS.
It has been previously demonstrated that the atheroscle-
rosis is a chronic inflammatory disease. Atherosclerotic le-
sions in large andmedium-sized arteries can contribute to the
ischemia of the heart, brain or extremities leading to infarc-
tion.4 Plaque rupture and thrombosis are the important
complications of the atherosclerotic lesions resulting in
ischemia. Some factors have been investigated regarding this
issue, and one of the main suspected factors is platelet
circulating in our blood flow. Platelets are a source of inflam-
matory mediators, and they are being influenced in contact
with artery surface. The activated platelets release the medi-
ators, and then, platelet adhesion and its atherothrombotic
potential can lead to the release of mediators, the progression
of inflammatory process, and the propagation of intra-
coronary thrombus predisposing to thrombotic events.4,5
Mean platelet volume (MPV), as a component of complete
blood count, is the most common and reliable index to iden-
tifying the platelet size and its activation status.6 An increased
MPV is associated with known cardiovascular risk factors,
including diabetes mellitus, hypertension, hypercholester-
olemia, and obesity.6e8 Some investigations have demon-
strated the correlation between elevatedMPV andACS,9,10 and
also the association between increased one and percutaneous
coronary intervention outcomes, including mortality and
stent restenosis.11e14 However, some studies have also shown
that MPV cannot be considered as either a marker of platelet
activation or a cardiovascular risk factor.6,15 In addition, other
platelet indices including platelet distribution width (PDW)
and platelet large cell ratio (P-LCR) have also been shown to be
correlated with ACS.9
Hereby, in the present study, our aimwas to determine any
correlations between the platelet indices, including platelet
count, MPV, PDW, and P-LCR and the spectrum of ACS among
patients who suffered from an acute new-onset chest
discomfort admitted to our emergency department.2. Materials and methods
2.1. Study patients
We prospectively enrolled 862 patients with a chief complaint
of acute chest discomfort suggestive of ACS who were
admitted to the emergency department of Seyyed-al-Shohada
Heart Center, Urmia, West-Azerbaijan province, Iran, from
August 2012 through April 2013. All patients whose chest pain
had been begun more than 30 min before arriving to the
hospital were excluded. This study was approved by our local
ethics committee in the Urmia University of Medical Sciences,
and all patients were provided written informed consent.The patients were hospitalized based on their evaluation at
admission, including taking history, physical examinations,
ischemic changes in a standard 12-lead electrocardiogram
(ECG), and/or increased cardiac biomarkers. The diagnosis of
MI was based on either patients who suffered from a chest
pain lasting more than 20 min with or without ST-segment
elevation in 2 contiguous leads and/or the elevation of car-
diac biomarkers (troponin or CK-MB) more than two-fold of
the upper limit of normal value or those who suffered from a
chest pain without ST-segment elevation associated with the
elevation of cardiac biomarkers. The UA was considered as
patients with typical chest pain and/or ischemic changes in
the 12-lead ECG without significant alteration in the cardiac
biomarkers similar to the MI cases. Non-ACS patients served
as patients whose chest pain was atypical and cardiac bio-
markers were not significant and/or no ischemic changes
were observed in the ECG. All admitted patients were given
300 mg of chewable aspirin before blood sample to be
collected. In addition, 184 healthy matched controls were also
enrolled to compare its measured laboratories with those of
patients who had acute chest pain. The control participants
had normal ECG without any history of chest pain or ischemic
heart diseases.
2.2. Biochemical evaluation
All patients underwent taking history and full physical ex-
amination associated with paraclinic evaluations, including
hematologic tests and a standard 12-lead ECG at admission.
Blood samples were collected using venipuncture for routine
hematologic assessments into tubes containing ethylenedi-
amine tetra-acetic acid (EDTA). The platelet indices were
analyzed within 30 min after sampling by an automated cell
counter (Sysmex KX21-N, Kobe, Japan). The troponin samples
showing positive qualitative test along with the ischemic
changes in ECG were reanalyzed to titrate.
2.3. Statistical analysis
The patients were categorized into four groups, including
control, non-ACS, UA, and MI. Continuous variables were re-
ported as mean ± standard deviation, and analyzed using
t-test, one-way ANOVA, and Tukey's post hoc test. Categorical
variables were also analyzed using Chi-square test. In addition,
the Pearson correlation coefficient was used for identifying
association between two continues variables. Receiver oper-
ating characteristic (ROC) curve was also constructed to detect
the accuracy of platelet volume indices for diagnosing ACS.
All analyses were performed using SPSS, version 16.0
(SPSS, Chicago, Illinois, USA). The p value of <0.05 was
considered statistically significant.3. Results
The study participants comprised of 1046 ones were divided
into four groups: (1) 184 controls; (2) 249 with non-ACS; (3) 421
with UA; and (4) 192 MI cases. The baseline clinical charac-
teristics and biochemical measurements were depicted in
Tables 1 and 2. The mean age of patients was significantly
Table 1 e Baseline characteristics of the patients with ACS and control subjects.
Control (n ¼ 184) Non-ACS (n ¼ 249) UA (n ¼ 421) MI (n ¼ 192) p-value*
Age (years) 52.8 ± 14.3 49.9 ± 15.1 60.5 ± 12.7 59.6 ± 12.6 <0.001
Tukey test** a a b b
Gender <0.001
Male 73 (39.7%) 152 (61%) 237 (56.3%) 139 (72.4%)
Female 111 (60.3%) 97 (39%) 184 (43.7%) 53 (27.6%)
BMI (kg/m2) 27.6 ± 4.7 28.1 ± 4.6 28.1 ± 4.8 27.3 ± 4.6 0.204
Tukey test** a a a a
Hypertension 1 (0.5%) 44 (17.7%) 251 (59.6%) 79 (41.1%) <0.001
Diabetes mellitus 0 (0%) 18 (7.2%) 122 (29%) 60 (31.2%) <0.001
Dyslipidemia 2 (1.1%) 15 (6%) 79 (18.8%) 28 (14.6%) <0.001
Smoking, current 30 (16.3%) 31 (12.4%) 107 (25.4%) 80 (41.7%) <0.001
Family history of CAD 32 (17.4%) 30 (12%) 130 (30.9%) 51 (26.6%) <0.001
Prior MI 0 (0%) 7 (2.8) 113 (26.8) 22 (11.5%) <0.001
Prior PCI 0 (0%) 7 (2.8%) 77 (18.3%) 4 (2.1%) <0.001
Drug history
b-blocker 3 (1.6%) 32 (12.9%) 211 (50.1%) 46 (24%) <0.001
Statins 0 (0%) 15 (6%) 195 (46.3%) 36 (18.8%) <0.001
Nitrates 0 (0%) 18 (7.2%) 173 (41.1%) 26 (13.5%) <0.001
Aspirin 0 (0%) 25 (10%) 252 (59.9%) 42 (21.9%) <0.001
Dual anti-platelet 0 (0%) 8 (3.2%) 105 (24.9%) 13 (6.8%) <0.001
ACS: acute coronary syndrome, BMI: body mass index, CAD: coronary artery disease, MI: myocardial infarction, PCI: percutaneous coronary
intervention, UA: unstable angina.
Values are presented as mean ± SD or number (%).
*p < 0.05 was considered statistically significant.
**Having the same letter indicates non-significant difference between two groups based on Tukey post hoc test.
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(p < 0.001), and also it was statistically greater in both groups
compared with that of non-ACS participants with similar
significances, p < 0.001 (Table 1). Most of the patients were
male in all groups except control subjects, and their differ-
ences were significant (p < 0.001). All cardiovascular risk fac-
tors and drug histories were also statistically significant
among groups (Table 1).
Platelet count was not significantly different among groups
(p ¼ 0.160), although its value was slightly higher in MI than in
UA or non-ACS cases (2.8% increase and 0.8% increase,
respectively). MPV level was significantly higher inMI patients
than that of non-ACS or control subjects (3.1% increase,
p¼ 0.003, and 4.1% increase, p¼ 0.019, respectively). PDW level
was also significantly higher in MI group compared with non-Table 2 e Biochemical measured values in the patients with A
Control (n ¼ 184) Non-ACS (n ¼
Platelet count (109/L) 234.7 ± 64.1 226.8 ± 62
Tukey test** a a
MPV (fL) 9.3 ± 0.9 9.4 ± 1
Tukey test** a a
PDW (fL) 11.9 ± 1.8 12.2 ± 1.9
Tukey test** a a
P-LCR (%) 21.3 ± 6.5 22.2 ± 7.5
Tukey test** a a, b, c
ACS: acute coronary syndrome, fL: femtoliter, MI: myocardial infarction,
platelet large cell ratio, UA: unstable angina.
Values are presented as mean ± SD.
*p < 0.05 was considered statistically significant.
**Having the same letter indicates non-significant difference between twACS or control groups (7.6% increase, p ¼ 0.033, and 9.8% in-
crease, p ¼ 0.005, respectively). The mean of P-LCR has only
been found to be significantly higher in MI and UA groups
compared with control group (11.25% increase, p ¼ 0.001, and
7.8% increase, p ¼ 0.018, respectively) (Table 2). Because the
females were more than males in control groups, we
compared the platelet indices in groups divided by gender.
Accordingly, there was no significant differences in terms of
platelet indices between both sexes, except platelet count that
was higher in female than male, p < 0.001 (Table 3).
When comparing the differences of platelet volume
indices, including MPV, PDW, and P-LCR between subgroups
by known cardiovascular risk factors among all patients irre-
spective being control or having chest pain, MPVwas found to
be significantly higher in patients who had a history ofCS and control subjects.
249) UA (n ¼ 421) MI (n ¼ 192) p-value*
.7 222.2 ± 64.9 228.7 ± 62.6 0.160
a a
9.5 ± 1 9.7 ± 1 0.002
a, b b
12.5 ± 2.1 13.2 ± 7.9 0.006
a, b b
23.1 ± 7.2 24 ± 7.5 0.001
b, c c
MPV: mean platelet volume, PDW: platelet distribution width, P-LCR:
o groups based on Tukey post hoc test.
Table 3 e Platelet indices of the patients with acute coronary syndrome (ACS) and control subjects based on sex difference.
Total (n ¼ 1046) Control (n ¼ 184) Non-ACS (n ¼ 249) UA (n ¼ 421) MI (n ¼ 192)
Platelet count (109/L)
Male 213.7 ± 57.2 220.36 ± 63.4 213.9 ± 57.6 210.1 ± 56 215.9 ± 55.6
Female 244.2 ± 68.2 244.2 ± 63 246.8 ± 65.5 237.8 ± 72 262.1 ± 68
p-value* <0.001 0.013 <0.001 <0.001 <0.001
MPV (fL)
Male 9.5 ± 1 9.4 ± 0.8 9.4 ± 1 9.5 ± 0.9 9.7 ± 1
Female 9.6 ± 1 9.3 ± 0.9 9.5 ± 1 9.7 ± 1.1 9.9 ± 1
p-value* 0.148 0.696 0.458 0.064 0.105
PDW (fL)
Male 12.4 ± 4.8 11.9 ± 1.7 12.1 ± 1.8 12.3 ± 2 13.2 ± 9.2
Female 12.4 ± 2.1 11.9 ± 1.8 12.3 ± 2 12.6 ± 2.2 13.1 ± 2.2
p-value* 0.978 0.969 0.493 0.122 0.933
P-LCR (%)
Male 22.5 ± 7.1 21.4 ± 6.1 21.9 ± 7.3 22.2 ± 6.9 23.4 ± 7.3
Female 23.1 ± 7.5 21.1 ± 6.7 22.6 ± 7.6 23.8 ± 7.6 25.6 ± 7.9
p-value* 0.148 0.754 0.479 0.100 0.071
ACS: acute coronary syndrome, fL: femtoliter, MI: myocardial infarction, MPV: mean platelet volume, PDW: platelet distribution width, P-LCR:
platelet large cell ratio, UA: unstable angina.
Values are presented as mean ± SD or number (%).
*p < 0.05 was considered statistically significant.
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(9.6 ± 1 vs. 9.4 ± 1 fL, p ¼ 0.005; 9.6 ± 1 vs. 9.4 ± 1 fL, p ¼ 0.023;
respectively). The participants with a history of hypertension
and ACS diagnosis had the higher P-LCR value compared with
themwithout both of those (23.7± 7.3 vs. 22.2± 7.2%, p¼ 0.002;
23.4 ± 7.3 vs. 22.2 ± 7.4%, p ¼ 0.032; respectively). In addition,
PDW was only significantly higher in cases with MI history
compared with those without it (13.3 ± 9.2 vs. 12.3 ± 2 fL,
p ¼ 0.006) (Fig. 1).
Pearson correlation analysis was used to determine the
correlations between platelet count and platelet volume
indices among all patients. Accordingly, There were strong
and negative correlations between platelet count and MPV
(r ¼ 0.390, p < 0.001), PDW (r ¼ 0.221, p < 0.001), and P-LCR
(r ¼ 0.398, p < 0.001). When comparing these correlations in
each group separately, all correlations were significant except
platelet count and PDW in MI cases, p ¼ 0.069 (Table 4).
Furthermore, ROC curve analysis demonstrated that the
admission values of MPV, PDW, and P-LCR were useful diag-
nostic tools to detect MI cases among patients suffering from
an acute chest discomfort (area under the curve [AUC]¼ 0.563,
95% confidence interval [CI] 0.519e0.607, p ¼ 0.006;
AUC ¼ 0.557, 95% CI 0.513e0.601, p ¼ 0.013; and AUC ¼ 0.560,
95% CI 0.515e0.604, p ¼ 0.010; respectively). The best cut-off
points, sensitivities, and specificities for identifying MI were
9.15 fL, 72%, and 40%; 11.35 fL, 73%, and 37%; and 20.25%, 68%,
and 44% for MPV, PDW, and P-LCR, respectively (Fig. 2).4. Discussion
We found that the platelet volume indices, including MPV,
PDW, and P-LCR increased in patients diagnosed with MI
compared with those with non-ACS or controls. These pa-
rameters were also found to be accurate diagnostic tests for
the detection of MI. These findings are in agreement with
those of previous studies showed that the elevated plateletvolume indices in patients with ACS can be used as prognostic
or diagnostic tests.2,9,10,16,17
Platelets are potential blood cells in terms of cardiovascular
disease mechanism. As the platelets increase in activity in the
setting of atherothrombotic events such as ACS, their size also
enhancesaccordingly. The largerone isbeingmore reactive and
producesmore proinflammatory and prothrombotic mediators
leading to coronary related clinical events. MPV is a routine
measurement of complete blood count showing the mean of
circulating platelet size, and its predictive value concerning
clinical assessments in the cardiovascular medicine has been
previously reported.6 In addition, it has been demonstrated that
theplatelet count is inversely associatedwithMPV,18 suggesting
that platelet consumption during acute coronary events can
lead to production of bigger one by megakaryocyte activity and
consequent elevated MPV value.19,20 Martin and coworkers21
demonstrated that MPV increased during 2 years follow up in
the patients diagnosed with MI, and elevated ones correlated
with recurrent MI and death. It was considered as an indepen-
dent predictor of recurrent MI; however, there was not any
correlation in terms of platelet counts between study groups.
They also showed no correlation between increased MPV and
known ischemic heart disease risk factors, including hyper-
tension, dyslipidemia, fibrinogen, white blood cell count, and
plasma viscosity. Other studies9,10 found that MPV values in
patients with MI increased compared with those of stable cor-
onary artery disease (CAD) or controls. None of the mentioned
investigations could show difference between MI and UA pa-
tients. We also could not show any differences betweenMI and
UA patients in terms of platelet indices values.
In addition, Khandekarand et al9 have evaluated the
platelet volume indices in the patients with MI and UA
compared with those with stable CAD and controls, and they
demonstrated that the elevated PDW and P-LCR were associ-
ated with developing ACS the same as MPV. By contrast,
Khode and coworkers17 have shown that there was no sig-
nificant differences in terms of PDW and P-LCR values
Fig. 1 e Platelet volume indices' difference among subgroups, each subgroup was categorized as either with a feature and a
prior history or without them: labeled yes or no. fL: femtoliter, MPV: mean platelet volume, PDW: platelet distribution width,
P-LCR: platelet large cell ratio.
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elevated MPV was associated with MI. We demonstrated that
elevated admission PDW and P-LCR were associated with MI
similar to MPV. Hereby, we believe that the diagnostic andprognostic values of platelet volume indices may be similar to
each other, but we need further prospective studies to eval-
uate the correlation between CAD and both the PDW and
P-LCR values to conclude more definitely.
Table 4eCorrelations between platelet count and platelet
volume indices among all patients.
Total Control Non-ACS UA MI
MPV
r 0.390 0.475 0.370 0.405 0.317
p-value* <0.001 <0.001 <0.001 <0.001 <0.001
PDW
r 0.221 0.476 0.358 0.407 0.132
p-value* <0.001 <0.001 <0.001 <0.001 0.069
P-LCR
r 0.398 0.483 0.360 0.429 0.306
p-value* <0.001 <0.001 <0.001 <0.001 <0.001
ACS: acute coronary syndrome, MI: myocardial infarction, MPV:
mean platelet volume, PDW: platelet distribution width, P-LCR:
platelet large cell ratio, UA: unstable angina.
*Pearson correlation was used.
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diagnostic accuracy ofMPV for ACS among patientswith chest
pain compared with non-cardiac chest pain. They concluded
that MPV measurement might be considered as the risk
stratification of patients with chest pain suggestive of ACS in
the emergency departments. Furthermore, a new meat-
analysis by Chu and colleagues6 stated that the increased
MPV was associated with recurrent MI and death during
follow up in the patients with MI, and coronary restenosis
following stenting. Based on these findings, it has been
remained unknown that whether MPV value will change
practice guidelines in cardiovascular medicine.Fig. 2 e Diagnostic accuracy of platelet volume indices.
Receiver operating characteristic (ROC) curves were
constructed to detect acute myocardial infarction (MI)
among healthy controls and patients suffering from an
acute chest pain. AUC: area under the curve, CI: confidence
interval, MPV: mean platelet volume, PDW: platelet
distribution width, P-LCR: platelet large cell ratio; Sens,
sensitivity, Spec: specificity.The other important study by Martin and colleagues20
concerning the role of platelets in coronary obstruction dur-
ing ACS concluded that the circulating larger and more active
platelets in ACS can influence therapeutic options in the
future; however, in a large scale study on 2009, De Luca and
colleagues15 found that there were not any correlations be-
tween MPV and platelet activity and the extension of CAD
according to coronary angiography and carotid intima media
thickness. They indicated that MPV cannot be considered
either as platelet activity marker or CAD risk factor.
None of the abovementioned investigations demonstrated
the difference of MPV between UA and MI. Notably, Mathur
and colleagues22 conducted a study in terms of the differen-
tiation between UA and MI by platelet activation indices, and
revealed that the MPV was lower in MI than that of UA. This
finding is contradictory to those of present and other studies
showing no difference, and supports this issue that we need
further investigations to elucidate the correlation between
platelet indices and patients with acute chest pain.
The limited numbers of literature have confirmed the
diagnostic accuracy of MPV in the setting of ACS. As they have
reportedMPV values as a diagnostic test for distinguishing the
development of ACS, including AUC¼ 0.661 reported by Lippi2
and AUC ¼ 0.800 reported by Chu,16 and also AUC ¼ 0.620 to
predict the occurrence of MI.17 Surprisingly, no study has
demonstrated neither diagnostic nor prognostic values of
PDW or P-LCR in the patients with ACS so far, and the present
study is the first one showing those practical values. It is
worth noting to mention that, all AUC values for platelet
volume indices were about 0.560; therefore it may be normal
to have cut-off values close to the mean of control partici-
pants, and relatively low sensitivities and specificities for our
markers may be attributable to either this point or the small
sample size of our cohort. Further large scale sized studies are
needed to examine this hypothesis again.
Platelet volume indices can be influenced by some factors
such as gender and taking anti-platelet agents. Accordingly,
we showed that there were no significant differences
regarding the platelet volume indices between both sexes in
all patients together and each gender separately. Further-
more, in the present study, all patients with acute chest pain
compatible with ACS were given aspirin following admission
and before blood sampling. Besides, the previous use of
aspirin or dual anti-platelet was also significantly higher in
the UA and MI groups compared with non-ACS or control
groups, and those uses were also higher in the UA than MI
group. However, there were no significant differences with
respect to the platelet volume indices between UA and MI
groups. Concerning this issue, Shah and et al23 have demon-
strated that MPV was a reproducible marker of platelet acti-
vation and did not influence by administering 81 mg of
aspirin. There was no study showing the impact of aspirin on
PDW and P-LCR, we believe that these markers may be the
same as MPV, but further studies considering the effects of
aspirin or other anti-platelet drugs on platelets are needed to
clarify this notion.
We found that the admission MPV, PDW, and P-LCR values
were higher in the patients with MI compared with those of
non-ACS or controls. In addition, our results did not show any
differences in terms of cardiac risk factors among groups,
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 6 2 2e6 2 8628except MPV and P-LCR, which were found to be higher in
participants who had hypertension or ACS as compared to
those did not, and PDW was only higher in patients with a
previous history of MI than those without it. Also of impor-
tance was that the platelet volume indices, including MPV,
PDW, and P-LCRwere found to be diagnostic tools to detect MI
among patients suffering from chest discomfort.
4.1. Study limitations
The main limitation of present study which I would note is
that we did not measure quantitatively troponin level and
platelet aggregability in all patients; hence comparing be-
tween these parameters and platelet volume indices have not
been evaluated. Comparing conventional cardiac markers
with platelet indices, in this setting, may be more useful than
those alone, as we did.5. Conclusion
This study showed that the elevated admission MPV, PDW,
and P-LCRmay be of benefit for detecting patients withMI and
for risk stratification of patients suffering from an acute chest
pain. Further large-scale and prospective studies are required
to elucidate the diagnostic and prognostic value of these pa-
rameters and those potential roles in defining new treatment
options for ACS.Conflicts of interest
All authors have none to declare.
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